{{Rsnum
|rsid=1080985
|Gene=CYP2D6
|Chromosome=22
|position=42528382
|Orientation=minus
|GMAF=0.1699
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=132
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}
[[rs1080985]] is a SNP near the [[CYP2D6]] gene. Depending on the publication source, it may be called "-1584C/G" or "1496C>G" or the like.

The wild type (normal) allele at this SNP is (C). The (G) variant indicates the presence of a non-wild type CYP2D6 variant, but it appears in many different variants so it can not be used to determine the presence of any particular variant.

The [[rs1080985]](G) allele defines the CYP2D6*2A variant, which has been reported to have relatively normal function yet in some cases may also lead to the intermediate metabolism phenotype.{{PMID|11037799}}

{{PMID Auto
|PMID=19604081
|Title=Relevance of CYP2D6 -1584C&gt;G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients
}}
{{PMID Auto
|PMID=19738170
|Title=Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease
|OA=1
}}

Please be careful when interpreting results for this SNP as it is in dbSNP and SNPedia in minus orientation where the risk allele is G, but test results are usually in plus orientation where the risk allele is C. This SNP has an [[ambiguous flip]] which can make this very confusing.

{{PMID|18547414|OA=1
}} Genotyping panel for assessing response to cancer chemotherapy.

{{PMID|22465999}} Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease Patients.

{{PMID Auto
|PMID=22688145
|Title=Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters
}}

{{PMID Auto
|PMID=23133420
|Title=Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}